CNS Pharma Q2 net loss $4.0M; Berubicin GBM trial enrollment at 180; topline data expected Q4 2023

CNS Pharmaceuticals, Inc.

2023-Q2 EPS reported -$3.10

Net loss $4.0M for Q2 2023 vs $3.6M in Q2 2022; R&D expense $2.8M (up from $2.2M).
Cash $4.3M as of June 30, sufficient into Q4 2023 through interim data readout.
Berubicin GBM trial enrollment ~75% (180 of 240 patients); topline interim results expected Q4 2023.
Company reiterated upcoming milestones: enroll 200th patient in Q3, complete enrollment in Q4.
Investigation into naked short selling; believes majority of activity identified and eliminated.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CNS Pharmaceuticals, Inc. reported the quarter ended June 30, 2023 results: net income The net loss for the three months ended June 30, 2023 was approximately $4.0 million.

Period: the quarter ended June 30, 2023
Net income: The net loss for the three months ended June 30, 2023 was approximately $4.0 million
Result: reported results

Exact text from the filing

On August 14, 2023, CNS Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the period ended June 30, 2023 and recent operational highlights.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

CNS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-005641

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.